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ABSTRACT
Aims The analysis of randomized controlled trials with incomplete binary outcome data is challenging. We develop
a general method for exploring the impact of missing data in such trials, with a focus on abstinence outcomes.
Design We propose a sensitivity analysis where standard analyses, which could include ‘missing = smoking’ and ‘last
observation carried forward’, are embedded in a wider class of models. Setting We apply our general method to data
from two smoking cessation trials. Participants A total of 489 and 1758 participants from two smoking cessation
trials. Measurements The abstinence outcomes were obtained using telephone interviews. Findings The estimated
intervention effects from both trials depend on the sensitivity parameters used. The findings differ considerably in
magnitude and statistical significance under quite extreme assumptions about the missing data, but are reasonably
consistent under more moderate assumptions. Conclusions A new method for undertaking sensitivity analyses when
handling missing data in trials with binary outcomes allows a wide range of assumptions about the missing data to be
assessed. In two smoking cessation trials the results were insensitive to all but extreme assumptions.
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analysis, smoking cessation trials.
Correspondence to: Dan Jackson, MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 0SR, UK.
E-mail: daniel.jackson@mrc-bsu.cam.ac.uk
Submitted 29 April 2013; initial review completed 11 November 2013; final version accepted 14 August 2014
INTRODUCTION
Missing outcome data are a common problem in
randomized controlled trials. In this paper we focus on
trials where the end-point of interest is a single binary
outcome. Binary outcome measures are widely used in
trials for smoking, alcohol and drug misuse where the
treatment goal is abstinence [1–4].
In smoking cessation trials, participants who do not
report their smoking status at follow-up are often
assumed to be smoking [5–8], and the Russell Standard
[9,10] requires this. Because smoking cessation trials
have this standard approach for handling missing
outcome data, we use smoking as our example and incor-
porate the Russell Standard into our methods. However,
our method is applicable to all trial areas where binary
outcome data are collected; for example, Maisel et al. [2]
found that most studies in their meta-analysis of treat-
ments for alcohol-use disorders considered dropouts to
have relapsed. Based on an informal review, we estimate
that around 80% of reports of smoking cessation trials
make the ‘missing = smoking’ assumption.
There are two distinct arguments for treating missing
values as smoking. First, we may define a composite
outcome of ‘either smoking or missing value’. We are
then making no assumption about the missing data, but
at the cost of addressing a question with little clinical
interest, as health benefit derives from quitting smoking,
even if this is not reported. This paper instead considers
smoking/quitting as the outcome of main clinical inter-
est. With this outcome, treating missing values as
smoking corresponds to making the assumption that any
individual with a missing value is smoking. This assump-
tion must be plausible to justify the analysis. Foulds et al.
[11] provide some relevant evidence: they telephoned
study participants who missed appointments in a
hospital-based smoking cessation trial and reported that
they all had resumed smoking.
A related, but different, approach is last observation
carried forward (LOCF). LOCF imputes any missing data
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with the last observed value, but is widely criticized
[12,13]. A similar idea is baseline observation carried
forward (BOCF), which assumes that participants with
missing data have reverted to their baseline behaviour
and replaces missing data with baseline values. If the
outcome is only measured once after randomization,
LOCF is the same as BOCF. In smoking cessation trials
where all participants are smoking at baseline BOCF is the
same as ‘missing = smoking’, but in our iQuit example
(Example 2: the iQuit trial) some participants met the trial
criteria to be considered not smoking at baseline.
Missing not at random (MNAR) means that the prob-
ability of an outcome being observed or not depends on the
unobserved outcomes [14]. This is entirely reasonable in
the context of smoking cessation trials, because it is plau-
sible that there is an association between participants’
smoking status and the probability that this status is
observed. In particular, the ‘missing = smoking’ assump-
tion is one example of an MNAR model. A recent paper by
Hedeker et al. [5], whose methods were subsequently
adopted by Smolkowski et al. [7], uses logistic regression to
model the association between the study outcome and
missingness, and uses the outcome at a previous time-
point in this regression to predict the missing values; treat-
ment effects are estimated using multiple imputation.
Under the assumption that data are missing at random
(MAR), we assume instead that the participants’ missing
outcomes are independent of the missing data indicator
(see below), given the covariates and any observed out-
comes. It is important to make it clear which covariates are
being used in this definition. We perform analyses assum-
ing two versions of MAR: using randomized group alone
or also using an additional binary covariate.
In practice, it is very difficult to say which of the above
assumptions about missing data is correct. Our approach
allows the analyst to investigate a range of plausible pos-
sibilities, as we illustrate in the Supporting information
appendix that shows our results for the iQuit data.
In this paper we describe a model for missing outcome
abstinence data that extends the procedure suggested by
Hedeker et al. [5] in the following ways. First, unlike
Hedeker et al., we include treatment group in the ‘impu-
tation’ model (our model 1 below includes the treatment
group as a covariate). This is important, because it allows
the possibility of different missing data mechanisms to
operate in different treatment arms, which may be plau-
sible when participants are subject to very different treat-
ments and so fail to provide data for different reasons.
Secondly, Hedeker et al. used formulae for standard errors
which assume that the unidentifiable parameters are esti-
mated using the data. We show how to obtain standard
errors which take into account the fact that some param-
eters are provided by the analyst, rather than estimated
from the data. Thirdly, we provide a spreadsheet which
enables calculation of intervention effects and standard
errors to be performed quickly without resorting to mul-
tiple imputation.
STATISTICAL MODEL
We present our model in terms of smoking cessation
trials, so that the binary end-point of interest is smoking
cessation. Hence, assuming ‘missing = smoking’ follows
the Russell Standard [9,10]. The corresponding assump-
tion in trials of treatments for alcohol or substance
misuse would be ‘missing = drinking’ or ‘missing =
using’. We embed the Russell standard in our method, so
the analyst is free to move away from this as much, or as
little, as desired.
Smoking status at a previous time-point is commonly
measured and may be useful in predicting participants’
smoking status at the end of the trial. We denote this
variable by X, so that X = 0 means that the participant
abstained from smoking at this time-point and X = 1 oth-
erwise, but more generally X may denote any binary
covariate. If X measures a quantity other than the
outcome at a previous time-point then the interpretation
of some models as corresponding to LOCF below is lost.
We assume that data on X are complete. If no such vari-
able X is available, we drop this variable from our model.
We assume a single binary outcome Y, which takes
the value 1 if the participant is smoking and 0 if they
have abstained from smoking at the end of the trial. We
use R to denote the missing data indicator, so that R = 1
means that Y is observed and R = 0 means that it is
missing. We let Z denote the randomized group and
assume there are two such groups; Z = 0 indicates that
the participant was randomized to the control group and
Z = 1 indicates the treatment group.
We follow, but extend, Hedeker et al. [5] by allowing a
treatment group effect in their model (6) and assume
that:
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The parameters β1, β3, β5 and β7 denote the log-odds of
participants smoking in particular subsets where
smoking status is observed, as summarized in Table 1.
Hence β1, β3, β5 and β7 are identifiable, and are estimated
as the log-odds of smoking in each (X, Z) group, using
data from participants whose smoking status is known.
The parameters β2, β4, β6 and β8 denote the log-odds
ratio of smoking for particular subsets of participants,
comparing those with missing outcomes to those with
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observed outcomes, as summarized in Table 2. The
parameters β2, β4, β6 and β8 relate the success of partici-
pants with missing outcomes to their counterparts whose
outcomes are observed. Hence, the data provide no infor-
mation about these parameters and so they will be held
fixed to particular values in the context of a sensitivity
analysis. A range of values will be chosen to correspond to
the kinds of assumptions described in the Introduction
and other values that are considered plausible.This kind of
approach has been suggested previously in the context of
meta-analysis by Higgins et al. [15], who describe the
exponential of parameters similar to those in Table 2 as
informatively missing odds ratios (IMORs).
Interpretation of the even-numbered β parameters
If all of β2, β4, β6 and β8 are zero, then in each (X, Z) group
the distribution of the outcome Y is the same for both
R = 0 and R = 1. Hence, Y and R are conditionally inde-
pendent and β2 = β4 = β6 = β8 = 0 corresponds to MAR.
Hence, the MAR assumption is a special case of our
model 1. If we make the weaker assumption that
β2 = 0, for example, then we assume that data in the
(X = 0, Z = 1) group are MAR. Similarly, if we assume
β2 = β4 = 0 then we assume the treatment group data are
MAR, and so on.
Another possible assumption is LOCF. If we let β2 be
large and negative, then missing values in the (X = 0,
Z = 1) group are taken to be non-smokers, and so
Y = 0 = X, and we have LOCF in this group. If instead
we let β2 be large and positive then we assume
‘missing = smoking’ in this group. Hence β2 = 0 can
be seen to be a compromise between LOCF and the
‘missing = smoking’ assumption for the (X = 0, Z = 1)
group. Conversely, large and positive values of β4 corre-
spond to both LOCF and ‘missing = smoking’ in the
(X = 1, Z = 1) group. Similar arguments apply for β6 and
β8. A range of possibilities is summarized in Table 3. The
infinite values for parameters in Table 3 correspond to the
type of assumptions often made when encountering
missing data. We allow the assumptions made about the
missing outcome data to differ in the two treatment
groups, although making the same assumption in both
groups, so that β2 = β6and β4 = β8 may often be consid-
ered plausible.
ESTIMATION
Estimating the intervention effect
The target parameter for inference is the intervention
effect:
α = = =( )− = =( )logit logitP Y Z P Y Z1 1 1 0| | (2)
which is the log odds ratio measuring the association
between treatment group and smoking.X plays an impor-
tant role as a predictor for any missing outcome data but
does not contribute to the definition of the target param-
eter. Using the definition of Y adopted here, a negative α
Table 1 Summary of odd-numbered β parameters: each param-
eter denotes the log-odds of smoking in a particular subset where
smoking status is observed.
Parameter Previous (X)
Treatment
group (Z) Observed(R)
β1 0 (not smoking) 1 (treatment) 1 (yes)
β3 1 (smoking) 1 (treatment) 1 (yes)
β5 0 (not smoking) 0 (control) 1 (yes)
β7 1 (smoking) 0 (control) 1 (yes)
Table 2 Summary of even-numbered β parameters: each
parameter denotes the log–odds ratio of smoking, comparing
participants with missing relative to those with observed out-
comes, in a particular subset of participants.
Parameter Previous (X)
Treatment
group (Z)
β2 0 (not smoking) 1 (treatment)
β4 1 (smoking) 1 (treatment)
β6 0 (not smoking) 0 (control)
β8 1 (smoking) 0 (control)
Table 3 Some possible assumptions about the missing outcome
data, expressed in terms of the even-numbered β parameters.
Assumptions for a particular group (X, Z) are shown only for the
group (X = 0, Z = 1) for brevity.
Assumption Interpretation
β2 β4 β6 β8
0 0 0 0 All data are MAR
0 – – – Data in the (X = 0, Z = 1) group are MAR
0 0 – – Data in the treatment group are MAR
– – 0 0 Data in the control group are MAR
−∞ +∞ −∞ +∞ All data LOCF
−∞ – – – Data in the (X = 0, Z = 1) group LOCF
−∞ +∞ – – Data in the treatment group LOCF
– – −∞ +∞ Data in the control group LOCF
+∞ +∞ +∞ +∞ All data missing = smoking
+∞ – – – Data in the (X = 0, Z = 1) group
missing = smoking
+∞ +∞ – – Data in the treatment group
missing = smoking
– – +∞ +∞ Data in the control group
missing = smoking
MAR = missing at random; LOCF = last observation carried forward.
+∞ = Large and positive; −∞ large and negative.
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indicates a beneficial treatment and so the corresponding
odds ratio of <1 also indicates a treatment benefit.
The estimation procedure is conceptually simple. First
we select the four values of the even numbered β sensi-
tivity parameters that we wish to use. We then estimate
the parameters β1, β3, β5and β7. As an example, we focus
on the 131 participants in the iQuit trial (see Example 2:
the iQuit trial) who are in the treatment group (Z = 1) and
are considered not smoking at baseline (X = 0). Of the 65
participants in this group who provide outcome data
(R = 1), 41 (63%) were smoking at the end of the trial
and so we estimate β1 to be logit(41/65) = 0.536.
Having estimated all four odd-numbered β param-
eters, we then use equation 1 to estimate the probability
of smoking for each combination of R, X and Z. In our
example, suppose we choose β2 = 1. Then we estimate the
log odds of smoking among non-responders in the treat-
ment group considered not smoking at baseline (Z = 1,
X = 0, R = 0) as 0.536 + 1 = 1.536, so the proportion
smoking in this group is 82%. Similarly, for the 746 par-
ticipants who are in the treatment group and are consid-
ered smoking at baseline (Z = 1, X = 1), 286 provided
outcome data of whom 230 (80%) were smoking at
follow-up; and supposing β4 = 1 we estimate that 92% of
the 460 who did not provide outcome data were smoking
at follow-up.
Having estimated all the above probabilities, we use
the law of total probability to estimate the probability
of smoking in each treatment group. In our example,
the overall probability of smoking (combining respon-
ders and non-responders and combining those not
smoking and smoking at baseline) in the treatment group
is (65 × 63% + 66 × 82% + 286 × 80% + 460 × 92%)/
(65 + 66 + 286 + 460) = 85%. The procedure is repeated
in the control arm leading to an estimate α of the inter-
vention effect. A mathematical formula that is equivalent
to following this procedure is given in the Supporting
information.
Standard errors
We have developed an approximate standard error of the
estimated treatment effect. This is based on the delta
method. As both the delta method and the standard
formula for the variance of an empirical log odds ratio are
based on first-order Taylor Series expansions, these
approximate standard errors agree exactly when infinite
even β are used and when data are imputed following the
same assumption (Table 3). Therefore both the estimate α
(see section Estimating the intervention effect) and its
standard error agree with the results obtained from
simple imputation when the model is equivalent to
assuming ‘missing = smoking’ or ‘LOCF’ in the trial arms.
A document containing the proof of this for the LOCF
case, with a full derivation of the standard error, is avail-
able in the Supporting information. Both the estimates
and the standard errors take the β2, β4, β6 and β8 param-
eters as fixed and no uncertainty in their value is
accounted for when performing inference using a par-
ticular set of these sensitivity parameters. However, the
uncertainty in the odd-numbered β parameters, and
therefore in the inferred quit rates, is taken into account.
A range of plausible values for the sensitivity values
should be explored, so that the implications of using dif-
ferent values can be assessed.
An equivalence between assuming MAR and a
complete case analysis
As explained above, if no X variable is available we drop
this from our model. MAR (where Z is now the only
covariate) now results in the same inference as a standard
complete case logistic regression of Y on Z.
Software
Our model and mode of analysis is sufficiently straight-
forward that all the results can be produced by our
purpose-built spreadsheet. Our spreadsheet is provided as
part of the Supporting information that accompanies this
paper. This spreadsheet can be used to reproduce the
results that follow and by those wishing to conduct
similar sensitivity analyses for their data. Our spread-
sheet also converts the results using the log odds ratio as
the measure of treatment effect to results using the risk
difference and the log relative risk. This requires changing
the logit function in equation 2 to the identify function
and the log function for the risk difference and log relative
risk, respectively.
APPLICATION TO THE EXAMPLE
DATA SETS
Example 1: Hedeker’s data
This study [4,16] evaluated the effectiveness of adding
group-based treatment adjuncts to a smoking cessation
intervention. Two types of group adjuncts were com-
pared. We follow Hedeker et al. and combine the controls
and ‘no-shows’ to provide the ‘control’ group and the two
active treatments to provide the ‘treatment’ group, but we
also recognize that this is dubious and only provides an
illustrative analysis. The pattern of missingness by treat-
ment group is shown in Table 4. There is an appreciably
larger proportion of missing outcome data in the control
group.
We will perform a range of analyses that show how
the inferences change depending on the assumptions
made about the missing outcome data. We refer to this as
a sensitivity analysis.
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We first perform the analysis described above (‘An
equivalence between assuming MAR and a complete case
analysis’), a logistic regression of Y on Z. This is equiva-
lent to assuming data are MAR, and making no use of the
covariate X.
In order to illustrate our method, we then make a
range of alternative assumptions about the missing
outcome data in both treatment groups. Some results are
shown in Table 5. ‘Missing = smoking’ imputes only
smokers; as the majority of participants whose outcome
is known at the end of the trial are smoking, this assump-
tion has little impact in reducing the standard error. LOCF
artificially reduces the standard error of the treatment
effect because it imputes some non-smokers.
In order to further illustrate our method, additional
results can be obtained by making alternative assump-
tions in each (X, Z) group, as shown in Table 3, or by
assuming finite, but non-zero, values of even β. For
example, Hedeker et al. [4] consider stratified odds ratios
of 1, 2 and 5, which correspond to 0 (MAR), log(2) and
log(5) for the even β parameters. A similar approach can
be adopted here by producing results similar to those in
Table 5 but where infinite values of β are replaced by, for
instance, log(2). Infinite values of β that correspond to
‘missing = smoking’ or LOCF in Table 5 are now replaced
with more moderate assumptions: that participants with
missing data are more likely to be smoking, or continue to
provide their last observed value, than their counterparts
with complete outcome data, respectively. The results are
shown in Table 6 and follow similar trends as in Table 5,
but all estimates bear much more resemblance to those
from a MAR analysis, as expected. Overall, we conclude
that the inferences from these data are not very sensitive
to the assumptions made about the missing data.
Example 2: the iQuit trial
The iQuit trial [17] is an internet-based randomized con-
trolled trial conducted among the general population of
smokers seeking help from web-based resources. It
assessed the effect on smoking cessation rates of self-help
materials tailored to individual smoker characteristics
compared with generic self-help materials. We used the
same methodology as in the previous example for analys-
ing these data. However, here we elicit plausible values for
the sensitivity parameters and use only these values. See
the Supporting information for further details.
IMPLICATIONS FOR THE DESIGN OF
TRIALS
Perhaps the most important and obvious implication of
the results obtained for our two examples is that we
should attempt to minimize the amount of missing data
[18]. If some missing outcome data are inevitable then
we suggest four possible strategies to reduce their impact.
First, collecting data on the reasons for missing data is
important in order to determine the kinds of assump-
tions that are plausible. For example, if data are missing
because a participant has moved away then the assump-
tion that their data are MAR may be entirely plausible.
Secondly, collecting outcome data from participants at
intermediate time-points is extremely valuable. Any addi-
tional outcome measurements provide more observed
data to condition on in the definition of MAR and so make
this more plausible [19–21]. A likelihood-based MAR
analysis using all outcome data could then be performed
using a mixed-effects model, where the dependence
between outcomes from the same individual are taken
into account. This type of analysis also allows partici-
pants who provide an outcome at some point, but not
necessarily the final outcome, to contribute to the analy-
sis. However, this type of approach is more difficult with
binary, rather than continuous, outcome data [22].
Thirdly, recording the number of attempts made to
obtain final outcome data, or possibly some other
measure of the difficulty in obtaining data, is useful
because this provides a means to determine how far the
data depart from MAR [23–25]. Hence, some of the pos-
sibilities examined in the sensitivity analyses performed
here might be ruled out because they are not supported
by the number of attempts data and modelling.
Finally, covariates related to missingness can be col-
lected and used in the analysis model to make the MAR
assumption more plausible.
DISCUSSION
Analysis of a randomized trial in addictions should start
with a ‘main analysis’ which is valid under a pre-specified
assumption about the missing data [26]. Often the
assumption underlying the main analysis is ‘missing
= smoking’. This assumption is thought to be conserva-
tive, but this need not be the case; further, it is question-
able if conservatism is desirable, because this reduces the
probability of successfully detecting an effective treat-
ment. Nelson et al. [27] state that Lichtenstein & Glasgow
[28] only suggested ‘missing = smoking’ as a conserva-
tive approach for estimating abstinence rates (and not for
comparing abstinence rates, as we do here).
Because assumptions such as ‘missing = smoking’ are
unlikely to be exactly true, sensitivity analysis is essential
Table 4 The pattern of missingness for Hedeker’s data.
Control Treatment Total
Smoking known 216 (72%) 156 (82%) 372 (76%)
Smoking unknown 83 (28%) 34 (18%) 117 (24%)
Total 299 190 489
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[26]. Our method provides an easy way to perform such
sensitivity analysis. First, plausible ranges of values of
the even β parameters should be defined, ideally before
the data are analysed, as in the Supporting information
appendix showing our results for the iQuit data. This Sup-
porting information appendix provides guidance, but not
strict guidelines, for those using our method. Then the
intervention effect should be computed over these ranges
of values of the even β. If the conclusions about the inter-
vention effect are unchanged in all sensitivity analyses
then the conclusions may be regarded as robust. The
results of the sensitivity analysis may be regarded as an
improvement on the results of the main analysis if the
ranges of values of the even β are reasonable, because
they are more likely to include the true value of the inter-
vention effect. Unfortunately, because the observed data
do not give us any information about the missing data,
there is usually no way of knowing if any given analysis
with missing data is correct. Thus any analysis is only as
good as the plausibility of its assumptions: our claim is
that sensitivity analysis can achieve greater plausibility
by encompassing a wider range of assumptions.
The proposed method is relatively easily imple-
mented. Models with a more complicated data structure
X to predict missingness are a relatively straightforward
extension of our method, where we specify model 1 for
all combinations of X, R and Z, and we sum over all
combinations of X and R for each treatment group sepa-
rately in equation 2. If X were continuous we would
instead integrate over X. However, with richer and more
complicated data comprising X, one would almost cer-
tainly have to assume common β parameters in model 1
for some of the resulting groups of participants, in order
to reduce the amount of modelling required. Further
treatment groups can be added easily and pairwise
treatment comparisons can be made using the estimate
for each treatment pair.
We have assumed that the target for inference is the
unadjusted log odds ratio of the association between the
outcome and the randomized group. We anticipate that
this will commonly be the case for randomized controlled
trials with binary outcomes. However, extending the
method to allow alternative measures of treatment effect,
such as risk differences or relative risks, is straight-
forward and our spreadsheet also estimates these two
measures. We proposed our method for estimating α
because it reduces to the usual unadjusted estimates
that are obtained when imputing values assuming
Table 5 Results from the sensitivity analysis for Hedeker’s data. The notation treatment/control in the Assumption column refers to
the assumption made in the treatment and control groups, respectively.
β2 β4 β6 β8 Assumption α (Standard error) OR (95% CI)
– – – – MAR (ignoring X; section 3.3) −0.35 (0.26) 0.71 (0.43,1.17)
0 0 0 0 MAR (using X and Z) −0.33 (0.25) 0.72 (0.44, 1.18)
−∞ +∞ −∞ +∞ LOCF −0.39 (0.22) 0.68 (0.44, 1.03)
+∞ +∞ +∞ +∞ ‘Missing = smoking’ −0.48 (0.25) 0.62 (0.38, 1.01)
0 0 −∞ +∞ MAR/LOCF −0.21 (0.23) 0.81 (0.51, 1.28)
0 0 +∞ +∞ MAR/’missing = smoking’ −0.74 (0.25) 0.48 (0.29, 0.78)
−∞ +∞ 0 0 LOCF/MAR −0.51 (0.24) 0.60 (0.38, 0.95)
−∞ +∞ +∞ +∞ LOCF/’missing = smoking’ −0.92 (0.23) 0.40 (0.25, 0.63)
+∞ +∞ 0 0 ‘Missing = smoking’/MAR −0.08 (0.25) 0.93 (0.57, 1.52)
+∞ +∞ −∞ +∞ ‘Missing = smoking’/LOCF 0.05 (0.23) 1.05 (0.67, 1.65)
MAR = missing at random; LOCF = last observation carried forward; OR = odds ratio; CI = confidence interval.
Table 6 Further results from the sensitivity analysis of Hedeker’s data. Standard errors of â and the confidence interval (CI) for the
odds ratio (OR) are in parentheses.
β2 β4 β6 β8 α (Standard error) OR (95% CI)
−log(2) log(2) −log(2) log(2) −0.37 (0.25) 0.69 (0.43, 1.12)
log(2) log(2) log(2) log(2) −0.39 (0.25) 0.68 (0.41, 1.11)
0 0 −log(2) log(2) −0.33 (0.25) 0.72 (0.44, 1.17)
0 0 log(2) log(2) −0.49 (0.25) 0.61 (0.37, 1.01)
−log(2) log(2) 0 0 −0.37 (0.25) 0.69 (0.42, 1.13)
−log(2) log(2) log(2) log(2) −0.53 (0.25) 0.59 (0.36, 0.97)
log(2) log(2) 0 0 −0.23 (0.25) 0.79 (0.48, 1.30)
log(2) log(2) −log(2) log(2) −0.23 (0.25) 0.79 (0.49, 1.29)
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‘missing = smoking’ and LOCF, when appropriate sensi-
tivity parameters are used.
Alternative estimators of treatment effect are also pos-
sible; for example, one may wish to adjust the treatment
effect for baseline covariates. When the even-numbered
β parameters are infinite the proposed method is equiva-
lent to imputing successes or failures. Hence, adjusted
analyses could be performed on a variety of imputed data
sets in the context of a sensitivity analysis. However, we
leave the best way to perform an analysis with finite sen-
sitivity parameters and adjusted treatment effects as an
open question. If the outcome is recorded at more than
one follow-up time-point, then analyses assuming that
particular groups of participants’ data are MAR, or
instead using ‘missing = smoking’ or LOCF for some or all
groups, may also be performed by imputing outcomes
where appropriate and then fitting a (possibly general-
ized) mixed-effects model. Hence, a sensitivity analysis
akin to the one in Table 5 is computationally straightfor-
ward. The best way to generalize our full model for a
longitudinal trial remains an open research question, but
pattern mixture modelling [12] provides a wide range of
possibilities.
To summarize, by using our method triallists working
in all areas can perform a thorough sensitivity analysis
and assess the consequences of a wide range of assump-
tions for the estimated treatment effect. These assump-
tions include the Russell Standard for smoking cessation
trials and we hope that this paper will encourage triallists
to consider using our approach.
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